Curis, Inc. (CRIS)

Market Cap	76.44M
Revenue (ttm)	10.41M
Net Income (ttm)	-58.96M
Shares Out	93.79M
EPS (ttm)	-0.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	448,171
Open	0.79
Previous Close	0.793
Day's Range	0.765 - 0.82
52-Week Range	0.68 - 5.27
Beta	2.67
Analysts	Buy
Price Target	9.95 (+1,143.8%)
Earnings Date	Nov 9, 2022

About CRIS

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, a...

• Industry: Biotechnology
• IPO Date: Aug 1, 2000
• CEO: James Dentzer
• Employees: 60
• Stock Exchange: NASDAQ
• Ticker Symbol: CRIS

Full Company Profile

Financial Performance

In 2021, Curis's revenue was $10.65 million, a decrease of -1.72% compared to the previous year's $10.84 million. Losses were -$45.44 million, 51.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CRIS stock is "Buy." The 12-month stock price forecast is 9.95, which is an increase of 1,143.75% from the latest price.

Price Target

$9.95

(1,143.75% upside)

Analyst Consensus: Buy

Stock Forecasts